Novo Nordisk announced this month a new combo therapy for the treatment of diabetes.
Xultophy 100/3.6 3 will now be available in pharmacies across the U.S., offering a fusion of long-acting basal insulin Tresiba and peptide-1 receptor agonist therapy Victoza in a once-daily injection delivery system.
Xultophy 100/3.6 is intended as treatment for adults with type 2 diabetes, specifically which are not well managed with basal insuling or liraglutide; it should be combined with diet and exercise for full effectiveness.
"Now that Xultophy 100/3.6 is available, patients with type 2 diabetes who are uncontrolled on basal insulin have a new combination that can help achieve their individualized treatment goals," Dr. Steve Edelman said.
The drug has been proved to lower blood sugar levels for 24 hours.
Eligible individuals may qualify for a savings card which will result in co-pays for as little a $1 each day, or $30 for a month's supply.
Alerts Sign-up